Pertussis over two decades: seroepidemiological study in a large population of the Siena Province, Tuscany Region, Central Italy

Serena Marchi, Emanuele Montomoli, Edmond J Remarque, Geraldo Tadinho Monteverde Spencer, Angela Azzarello, Simonetta Viviani, Claudia Maria Trombetta, Serena Marchi, Emanuele Montomoli, Edmond J Remarque, Geraldo Tadinho Monteverde Spencer, Angela Azzarello, Simonetta Viviani, Claudia Maria Trombetta

Abstract

Objectives: To evaluate seroprevalence against Bordetella pertussis in Tuscany, a large Italian region, from 1992 to 2005 and from 2013 to 2016.

Design: Seroepidemiological study.

Participants: 1812 serum samples collected in Tuscany from subjects older than 12 years from 1992 to 2005 and from 2013 to 2016.

Outcome measures: Specific antibody levels were determined by means of standard commercial ELISA using a dual cut-off of 50 and 125 IU/mL as markers of past and recent infection/vaccination, respectively.

Results: The highest values of IgG titres were observed in 1992-1994 in all subjects (69.5 IU/mL), with prevalence values of subjects with IgG titres of >50 and >125 IU/mL of 68.3% and 23.8%, respectively. IgG titres decreased in the years thereafter (37.8 IU/mL in 2002-2005), together with prevalence values (41.7% and 8.1% in 2002-2005). In 2013-2016, both IgG titres and prevalence values showed a slight increase (50.6 IU/mL, 53.9% and 14.7%, respectively). IgG titres and prevalence followed the same age-related trend in all time periods considered, with the highest values in subjects aged 12-22 years. The lowest values were found in the age group of subjects aged 23-35 years (OR 0.54).

Conclusions: Since 2002, approximately half of the population over 22 years of age have low IgG titres and are presumably susceptible to acquiring and transmitting pertussis infection. In addition, in 2013-2016, almost one-third of subjects aged 12-22 years, that is, the age group most likely to have been vaccinated against pertussis in infancy, had low antibody levels. Improving vaccination coverage and implementing careful surveillance are therefore recommended in order to prevent morbidity and mortality due to pertussis.

Keywords: Italy; Tuscany; epidemiology; pertussis.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Top panel: pertussis IgG titres by sampling period and age group. Individual titres are plotted per sampling period (circles indicate female and triangles indicate male). Boxes indicate median and quartile ranges; orange and black dashed lines indicate antibody levels at 50 and at 125 IU/mL, respectively. Bottom panel: percentages of subjects with IgG titres of >50 IU/mL (orange) and >125 IU/mL (black) by sampling period and age group.
Figure 2
Figure 2
Estimates from analysis of variance and logistic regression analyses, all comparisons versus index, that is, age 12–22 in 1992–1994.

References

    1. WHO Pertussis vaccines: WHO position paper - September 2015. Wkly Epidemiol Rec 2015;90:433–58.
    1. Gabutti G, Rota MC. Pertussis: a review of disease epidemiology worldwide and in Italy. Int J Environ Res Public Health 2012;9:4626–38. 10.3390/ijerph9124626
    1. Chiappini E, Stival A, Galli L, et al. . Pertussis re-emergence in the post-vaccination era. BMC Infect Dis 2013;13:151 10.1186/1471-2334-13-151
    1. Tan T, Dalby T, Forsyth K, et al. . Pertussis across the globe: recent epidemiologic trends from 2000 to 2013. Pediatr Infect Dis J 2015;34:e222–32. 10.1097/INF.0000000000000795
    1. Zepp F, Heininger U, Mertsola J, et al. . Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011;11:557–70. 10.1016/S1473-3099(11)70007-X
    1. Binkin NJ, Salmaso S, Tozzi AE, et al. . Epidemiology of pertussis in a developed country with low vaccination coverage: the Italian experience. Pediatr Infect Dis J 1992;11:653–61.
    1. WHO Childhood vaccination coverage in Italy: results of a seven-region survey. The Italian vaccine coverage survey Working group. Bull World Health Organ 1994;72:885–95.
    1. Gonfiantini MV, Carloni E, Gesualdo F, et al. . Epidemiology of pertussis in Italy: disease trends over the last century. Euro Surveill 2014;19 10.2807/1560-7917.ES2014.19.40.20921
    1. Berti E, Chiappini E, Orlandini E, et al. . Pertussis is still common in a highly vaccinated infant population. Acta Paediatr 2014;103:846–9. 10.1111/apa.12655
    1. Salmaso S, Rota MC, Ciofi Degli Atti ML, et al. . Infant immunization coverage in Italy: estimates by simultaneous EPI cluster surveys of regions. ICONA Study Group. Bull World Health Organ 1999;77:843–51.
    1. Rota MC, D'Ancona F, Massari M, et al. . How increased pertussis vaccination coverage is changing the epidemiology of pertussis in Italy. Vaccine 2005;23:5299–305. 10.1016/j.vaccine.2005.07.061
    1. ICONA ICONA 2008: Indagine di COpertura vaccinale NAzionale nei bambini e negli adolescenti, 2009: 1–129.
    1. Ministero della Salute Vaccinazioni dell’et pediatrica e dell’adolescente – coperture vaccinali [Childhood and adolescent vaccination- Vaccine coverage]. Available: [Accessed 6 Nov 2017].
    1. ECDC Pertussis - Annual Epidemiological Report 2017, 2017: 1–2.
    1. Toscana ARS. La sorveglianza epidemiologica delle malattie infettive in Toscana, Rapporto Ottobre 2018, 2018.
    1. Palazzo R, Carollo M, Fedele G, et al. . Evidence of increased circulation of Bordetella pertussis in the Italian adult population from seroprevalence data (2012-2013). J Med Microbiol 2016;65:649–57. 10.1099/jmm.0.000264
    1. Yaari E, Yafe-Zimerman Y, Schwartz SB, et al. . Clinical manifestations of Bordetella pertussis infection in immunized children and young adults. Chest 1999;115:1254–8. 10.1378/chest.115.5.1254
    1. Cherry JD. Immunity to pertussis. Clin Infect Dis 2007;44:1278–9. 10.1086/514350
    1. de Greeff SC, de Melker HE, van Gageldonk PGM, et al. . Seroprevalence of pertussis in the Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS One 2010;5:e14183 10.1371/journal.pone.0014183
    1. Chiappini E, Berti E, Sollai S, et al. . Dramatic pertussis resurgence in Tuscan infants in 2014. Pediatr Infect Dis J 2016;35:930–1. 10.1097/INF.0000000000001198
    1. Wendelboe AM, Van Rie A, Salmaso S, et al. . Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005;24:S58–61. 10.1097/01.inf.0000160914.59160.41
    1. Klein NP, Bartlett J, Rowhani-Rahbar A, et al. . Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012;367:1012–9. 10.1056/NEJMoa1200850
    1. ECDC Guidance and protocol for the serological diagnosis of human infection with Bordetella pertussis, 2012: 1–21.
    1. Giammanco A, Chiarini A, Maple PAC, et al. . European Sero-Epidemiology Network: standardisation of the assay results for pertussis. Vaccine 2003;22): :112–20. 10.1016/S0264-410X(03)00514-0
    1. Misegades LK, Winter K, Harriman K, et al. . Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012;308:2126–32. 10.1001/jama.2012.14939
    1. Gustafsson L, Hessel L, Storsaeter J, et al. . Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 2006;118:978–84. 10.1542/peds.2005-2746
    1. Marchi S, Viviani S, Montomoli E, et al. . Low prevalence of antibodies against pertussis in pregnant women in Italy. Lancet Infect Dis 2019;19): :690 10.1016/S1473-3099(19)30269-5
    1. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010;17:1055–65. 10.1128/CVI.00131-10
    1. Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus–diphtheria–pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol 2011;204:334.e1–334.e5. 10.1016/j.ajog.2010.11.024
    1. Guiso N, Berbers G, Fry NK, et al. . What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. Eur J Clin Microbiol Infect Dis 2011;30:307–12. 10.1007/s10096-010-1104-y
    1. Fedele G, Leone P, Bellino S, et al. . Diagnostic performance of commercial serological assays measuring Bordetella pertussis IgG antibodies. Diagn Microbiol Infect Dis 2018;90:157–62. 10.1016/j.diagmicrobio.2017.11.006

Source: PubMed

3
Abonner